Endothelial cell-specific reduction of heparan sulfate suppresses glioma growth in mice
-
Published:2021-11-11
Issue:1
Volume:12
Page:
-
ISSN:2730-6011
-
Container-title:Discover Oncology
-
language:en
-
Short-container-title:Discov Onc
Author:
Kinoshita Takamasa, Tomita HiroyukiORCID, Okada HideshiORCID, Niwa Ayumi, Hyodo Fuminori, Kanayama Tomohiro, Matsuo Mikiko, Imaizumi Yuko, Kuroda Takahiro, Hatano Yuichiro, Miyai Masafumi, Egashira Yusuke, Enomoto Yukiko, Nakayama Noriyuki, Sugie Shigeyuki, Matsumoto Kazu, Yamaguchi Yu, Matsuo Masayuki, Hara Hideaki, Iwama Toru, Hara Akira
Abstract
Abstract
Purpose
Heparan sulfate (HS) is one of the factors that has been suggested to be associated with angiogenesis and invasion of glioblastoma (GBM), an aggressive and fast-growing brain tumor. However, it remains unclear how HS of endothelial cells is involved in angiogenesis in glioblastoma and its prognosis. Thus, we investigated the effect of endothelial cell HS on GBM development.
Methods
We generated endothelial cell-specific knockout of Ext1, a gene encoding a glycosyltransferase and essential for HS synthesis, and murine GL261 glioblastoma cells were orthotopically transplanted. Two weeks after transplantation, we examined the tumor progression and underlying mechanisms.
Results
The endothelial cell-specific Ext1 knockout (Ext1CKO) mice exhibited reduced HS expression specifically in the vascular endothelium of the brain capillaries compared with the control wild-type (WT) mice. GBM growth was significantly suppressed in Ext1CKO mice compared with that in WT mice. After GBM transplantation, the survival rate was significantly higher in Ext1CKO mice than in WT mice. We investigated how the effect of fibroblast growth factor 2 (FGF2), which is known as an angiogenesis-promoting factor, differs between Ext1CKO and WT mice by using an in vivo Matrigel assay and demonstrated that endothelial cell-specific HS reduction attenuated the effect of FGF2 on angiogenesis.
Conclusions
HS reduction in the vascular endothelium of the brain suppressed GBM growth and neovascularization in mice.
Funder
Japan Society for the Promotion of Science National Institutes of Health Japan Agency for Medical Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism
Reference43 articles.
1. Yamada T, Tsuji S, Nakamura S, Egashira Y, Shimazawa M, Nakayama N, Yano H, Iwama T, Hara H. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. J Neurosurg. 2020. https://doi.org/10.3171/2019.12.JNS192682. 2. Le Joncour V, Guichet PO, Dembele KP, Mutel A, Campisi D, Perzo N, Desrues L, Modzelewski R, Couraud PO, Honnorat J, Ferracci FX, Marguet F, Laquerriere A, Vera P, Bohn P, Langlois O, Morin F, Gandolfo P, Castel H. Targeting the urotensin II/UT G protein-coupled receptor to counteract angiogenesis and mesenchymal hypoxia/necrosis in glioblastoma. Front Cell Dev Biol. 2021;9: 652544. https://doi.org/10.3389/fcell.2021.652544. 3. Gao Y, Zheng H, Li L, Feng M, Chen X, Hao B, Lv Z, Zhou X, Cao Y. Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-kappaB signaling pathway. Front Cell Dev Biol. 2021;9: 598377. https://doi.org/10.3389/fcell.2021.598377. 4. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22. https://doi.org/10.1056/NEJMoa1308345. 5. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708. https://doi.org/10.1056/NEJMoa1308573.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|